Efficacy Study of Metformin Glycinate on Postprandial Lipemia
Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients
Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Listed as NCT02064881, this PHASE2/PHASE3 trial focuses on Type 2 Diabetes and remains ongoing. Sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, it has been updated 8 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
Status: Unknown Status → Recruiting
-
Jan 2017 — Feb 2018 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Laboratorios Silanes S.A. de C.V.
For direct contact, visit the study record on ClinicalTrials.gov .